Adolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington Jeremy Mennis, Gerald J. Stahler Drug and Alcohol Dependence, 2020, 210, 107960 Doi : 10.1016/j.drugalcdep.2020.107960 A B S T R A C T Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008–2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12–17 were used to model state treatment [...]
Lire la suiteThe role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia Huibing Tan, Tasha Ahmad, Michael Loureiro, Jordan Zunder and Steven R. Laviolette Frontiers in Psychiatry, 2014,Vol 5, Article 73, 1-12 doi : 10.3389/fpsyt.2014.00073 Emerging evidence from both basic and clinical research demonstrates an important role for endo-cannabinoid (ECB) signaling in the processing of emotionally salient information, learning, and memory. Cannabinoid transmission within neural circuits involved in emotional processing has been shown to modulate the acquisition, recall, and extinction of emotionally salient memories and importantly, can strongly modulate the emotional salience of incoming sensory information. Two neural regions in particular, the [...]
Lire la suiteReduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis Chad Purcell, Andrew Davis, Nico Moolman, and S. Mark Taylor Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, Doi : 10.1089/can.2018.0020 Abstract Background : Benzodiazepines are a class of medication with sedative properties, commonly used for anxiety and other neurological conditions. These medications are associated with several well-known adverse effects. This observational study aims to investigate the reduction of benzodiazepine use in patients using prescribed medical cannabis. Methods : A retrospective analysis was performed on a cohort of 146 medical cannabis patients (average age 47 years, 61% female, 54% reporting prior use of cannabis) who reported [...]
Lire la suitePharmacotherapy for the Treatment of Cannabis Use Disorder. A Systematic Review Karli K. Kondo, PhD; Benjamin J. Morasco, PhD; Shannon M. Nugent, PhD; Chelsea K. Ayers, MPH; Maya E. O’Neil, PhD; Michele Freeman, MPH, and Devan Kansagara, MD, MCR Annals of Internal Medicine, 2020, 172, 398-412. doi : 10.7326/M19-1105 Background : Cannabis use disorder (CUD) is a growing concern, and evidence-based data are needed to inform treatment options. Purpose : To review the benefits and risks of pharmacotherapies for the treatment of CUD. Data Sources : MEDLINE, PsycINFO, Cochrane Database of Systematic Reviews, and clinical trial registries from inception through September 2019. Study Selection : Pharmacotherapy trials [...]
Lire la suiteNeural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man : A Critical Review of Neuroimaging Studies Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Jose A. Crippa and Philip K. McGuire Current Pharmaceutical Design, 2012, 18, 5045-5054 Abstract Pharmacological challenge in conjunction with neuroimaging techniques has been employed for over two decades now to understand the neural basis of the cognitive, emotional and symptomatic effects of the main ingredients of cannabis, the most widely used illicit drug in the world. This selective critical review focuses on the human neuroimaging studies investigating the effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), the two main cannabinoids [...]
Lire la suiteFrequent Cannabis Use in Depression Tripled Over Past Decade Batya Swift Yasgur, MA, LSW Medscape, August 19, 2020 Not only are individuals with depression at significantly higher risk for cannabis use compared with those without depression, this trend has increased dramatically over the last decade, new research shows. Investigators analyzed data from more than 16,000 US adults between the ages of 20 and 59 years and found that those with depression had almost twice the odds of any past-month cannabis use compared with those without depression. Odds rose from 1.5 in the 2005-2006 period to 2.3 in the 2015-2016 period. Moreover, the odds ratio (OR) [...]
Lire la suiteCannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial Tom P Freeman, Chandni Hindocha, Gianluca Baio, Natacha D C Shaban, Emily M Thomas, Danica Astbury, Abigail M Freeman, Rachel Lees, Sam Craft, Paul D Morrison, Michael A P Bloomfield, Dominic O'Ryan, Jane Kinghorn, Celia J A Morgan, Ali Mofeez, H Valerie Curran The Lancet Psychiatry, 2020, doi : 10.1016/S2215-0366(20)30290-X Abstract Background : A substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to identify efficacious doses and eliminate inefficacious doses in a phase 2a trial using [...]
Lire la suiteThe association between cannabis use and mood disorders : A longitudinal study Daniel Feingold, Mark Weiser, Jürgen Rehme, Shaul Lev-Ran Journal of Affective Disorders, 2015, 172, 211–218. doi : 10.1016/j.jad.2014.10.006 a b s t r a c t Background : The association between cannabis use and mood disorders is well documented, yet evidence regarding causality is conflicting. This study explored the association between cannabis use, major depressive disorder (MDD) and bipolar disorder (BPD) in a 3-year prospective study. Methods : Data was drawn from waves 1 and 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). MDD and BPD were controlled at baseline [...]
Lire la suiteAdolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington Jeremy Mennis, Gerald J Stahler Drug and Alcohol Dependence, 2020 May 1, 210, 107960. doi : 10.1016/j.drugalcdep.2020.107960 Abstract Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008-2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12-17 were used to model state treatment admissions trends. [...]
Lire la suiteAprès la crise du Covid-19 il faut légaliser le cannabis, vite ! François-Michel LAMBERT député des Bouches du Rhône En juin 2019 avec une vingtaine de députés nous déposions une proposition de loi, relative « à la légalisation contrôlée de la production, de la vente et de la consommation de cannabis ». La même semaine le « conseil d’analyse économique », think tank rattaché à Matignon, préconisait dans un rapport très documenté la légalisation du cannabis récréatif et une tribune dans l’Obs signée par 70 médecins, économistes et élus nationaux et locaux, plaidait pour cette légalisation. Ces initiatives pour la légalisation du cannabis dénoncent [...]
Lire la suite